Bad News For Pharmaceutical Companies and For Consumers
First, there was Fen-Phen with its promises of weight loss, but which carried the additional benefits of valvular heart disease and pulmonary hypertension. Then there was Vioxx, an NSAID which delivered great benefits in treating arthritis, but only if you weren’t too concerned about the minor risks of heart attack and stroke. And [...]
RSS Feed
